Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Symphony Environmental Technologies (AIM: SYM) shares are rallying on Monday after the company announced it has entered into a “significant collaboration” with Meditechs Global Co Limited.
Meditech is the holding company of a group of glove manufacturers with factories in Malaysia and China, specialising in medical-grade nitrile disposable gloves.
The collaboration is via four separate agreements on distribution, manufacturing, marketing, and corporate investment.
“This collaboration is intended to accelerate and expand sales of d2w and d2p technologies and finished products in China and globally, through Meditech's established network of manufacturers and commercial end-users,” Symphony Environmental said in a statement.
For an initial 10 years, the distribution agreement has seen Symphony appoint Meditech as an authorised distributor for its d2w and d2p additive and masterbatch technologies in China.
As part of the manufacturing agreement, Meditech will purchase trial quantities of Symphony's d2p and d2w additives for manufacturing prototype batches of gloves containing d2p and/or d2w. It will also seek certification of the gloves for sale in the EU and the US under PPE, Medical Device and Food Contact regulations. The manufacturing agreement is for an initial five years.
A three-year deal has been agreed as part of the marketing agreement that has seen Meditech appoint Symphony as an authorised but non-exclusive global distributor for its nitrile gloves made with Symphony's d2p and/or d2w technologies.
And finally, as part of the corporate agreement, Meditech has agreed that it will, no later than 6 months from the date of the deal, acquire no less than 2.5% and no more than 20% of the total issued share capital of Symphony. They must also purchase the shares at no less than 35p each.
Michael Laurier, CEO of Symphony, said: “These agreements will provide Symphony with a much stronger presence in the Far East and will give us a secure supply of gloves made with our antimicrobial and/or biodegradable technology for our growing international trade in gloves. In addition, we welcome Meditech's agreement to invest in Symphony so that our commercial and corporate interests are more closely aligned.”
Symphony's share price has climbed over 20% to 27.05p following the announcement, adding to its year-to-date gains.
Symphony Environmental shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Symphony shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .